The Efficacy of Oral IMODTM in Oral Lichen Planus treatment;

A vast variety of local and systemic treatments have been utilized in the management of oral lichen planus (OLP). The efficiency of IMOD (an Iranian new immunomodulatory drug, containing selenium, carotene, and flavonoids) in the treatment of OLP was assessed.

Methods:

 In a randomized double-blind placebo/controlled trial study, 40 individuals (who referred to the oral and maxillofacial department of the School of Dentistry) with lichen planus were registered. The study enclosed a three-month period of therapy by IMOD (480 mg/day) (n=20) or placebo (n=20), and a three-month follow-up period after drug interruption. Consequence measures contain pain or burning severity, clinical score, clinical global impression of change (CGIC) and patient global impression of change (PGIC). Unstimulated saliva levels of total antioxidant capacity (TAC), Malondialdehyde (MDA), uric acid and TNF-α were tested at the baseline and after treatment and calculated their changes. Statistical analysis of MannWhitney and unpaired student’s t-test were used.

There were no noteworthy changes between placebo and IMOD treaded groups in pain or burning severity, clinical score, CGIC and PGIC following 2,4,8,12, and 24 weeks following treatment and also in saliva TAC, MDA, TNF-α and uric acid changes.

IMOD lacks proper efficacy in the management of severe or very severe OLP lesions.